Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Hemoglobin SC Disease With Hydroxyurea

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of HbSC disease~2. Score equal or lower than 80 on the PedsQL™ Sickle Cell Disease Module version 3.0~3. Have experienced a sickle cell disease related complication~Exclusion Criteria:~1. Failure to meet inclusion criteria.~2. Hydroxyurea usage in the last 3 months.~3. Chronic RBC transfusion therapy.~4. Packed red blood cell transfusion in the last 3 months (temporary exclusion).~5. Pregnancy, or refusal to use medically effective birth control if female and sexually active.

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Hydroxurea (Type: EXPERIMENTAL): Initiate hydroxyurea at 10 mg/kg daily and escalate hydroxyurea dose by 5 mg/kg/day every 8 weeks up to a maximum dose of 35 mg/kg/day if blood counts meet escalation criteria on at least 2 blood tests over eight weeks prior to dose increase.

Based on this trial design, predict the completion outcome and termination type (if applicable).